These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

505 related items for PubMed ID: 29183848

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
    Okamoto A, Asai T, Hirai Y, Shimizu K, Koide H, Minamino T, Oku N.
    Mol Pharm; 2018 Apr 02; 15(4):1495-1504. PubMed ID: 29502423
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. siRNA-loaded selenium nanoparticle modified with hyaluronic acid for enhanced hepatocellular carcinoma therapy.
    Xia Y, Guo M, Xu T, Li Y, Wang C, Lin Z, Zhao M, Zhu B.
    Int J Nanomedicine; 2018 Apr 02; 13():1539-1552. PubMed ID: 29588583
    [Abstract] [Full Text] [Related]

  • 26. Degradable hyaluronic acid/protamine sulfate interpolyelectrolyte complexes as miRNA-delivery nanocapsules for triple-negative breast cancer therapy.
    Wang S, Cao M, Deng X, Xiao X, Yin Z, Hu Q, Zhou Z, Zhang F, Zhang R, Wu Y, Sheng W, Zeng Y.
    Adv Healthc Mater; 2015 Jan 28; 4(2):281-90. PubMed ID: 25044638
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Antitumor effect of hyaluronic-acid-modified chitosan nanoparticles loaded with siRNA for targeted therapy for non-small cell lung cancer.
    Zhang W, Xu W, Lan Y, He X, Liu K, Liang Y.
    Int J Nanomedicine; 2019 Jan 28; 14():5287-5301. PubMed ID: 31406460
    [Abstract] [Full Text] [Related]

  • 29. Facial amphipathic deoxycholic acid-modified polyethyleneimine for efficient MMP-2 siRNA delivery in vascular smooth muscle cells.
    Kim D, Lee D, Jang YL, Chae SY, Choi D, Jeong JH, Kim SH.
    Eur J Pharm Biopharm; 2012 May 28; 81(1):14-23. PubMed ID: 22311297
    [Abstract] [Full Text] [Related]

  • 30. Induction of apoptosis by survivin silencing through siRNA delivery in a human breast cancer cell line.
    Montazeri Aliabadi H, Landry B, Mahdipoor P, Uludağ H.
    Mol Pharm; 2011 Oct 03; 8(5):1821-30. PubMed ID: 21838308
    [Abstract] [Full Text] [Related]

  • 31. Hyaluronic acid-conjugated lipoplexes for targeted delivery of siRNA in a murine metastatic lung cancer model.
    Leite Nascimento T, Hillaireau H, Vergnaud J, Rivano M, Deloménie C, Courilleau D, Arpicco S, Suk JS, Hanes J, Fattal E.
    Int J Pharm; 2016 Nov 30; 514(1):103-111. PubMed ID: 27863652
    [Abstract] [Full Text] [Related]

  • 32. "Smart" Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells.
    Kaushal N, Durmaz YY, Bao L, Merajver SD, ElSayed ME.
    Mol Pharm; 2015 Jul 06; 12(7):2406-17. PubMed ID: 26020100
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Chitosan layered gold nanorods as synergistic therapeutics for photothermal ablation and gene silencing in triple-negative breast cancer.
    Yang Z, Liu T, Xie Y, Sun Z, Liu H, Lin J, Liu C, Mao ZW, Nie S.
    Acta Biomater; 2015 Oct 06; 25():194-204. PubMed ID: 26193000
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Cationic derivatives of biocompatible hyaluronic acids for delivery of siRNA and antisense oligonucleotides.
    Han SE, Kang H, Shim GY, Kim SJ, Choi HG, Kim J, Hahn SK, Oh YK.
    J Drug Target; 2009 Feb 06; 17(2):123-32. PubMed ID: 19012052
    [Abstract] [Full Text] [Related]

  • 38. Hyaluronic acid-polyethyleneimine conjugate for target specific intracellular delivery of siRNA.
    Jiang G, Park K, Kim J, Kim KS, Oh EJ, Kang H, Han SE, Oh YK, Park TG, Kwang Hahn S.
    Biopolymers; 2008 Jul 06; 89(7):635-42. PubMed ID: 18322932
    [Abstract] [Full Text] [Related]

  • 39. Preclinical evaluation of cyclin dependent kinase 11 and casein kinase 2 survival kinases as RNA interference targets for triple negative breast cancer therapy.
    Kren BT, Unger GM, Abedin MJ, Vogel RI, Henzler CM, Ahmed K, Trembley JH.
    Breast Cancer Res; 2015 Jul 06; 17():19. PubMed ID: 25837326
    [Abstract] [Full Text] [Related]

  • 40. Synergistic inhibition of aggressive breast cancer cell migration and invasion by cytoplasmic delivery of anti-RhoC silencing RNA and presentation of EPPT1 peptide on "smart" particles.
    Kaushal N, Tiruchinapally G, Durmaz YY, Bao L, Gilani R, Merajver SD, ElSayed MEH.
    J Control Release; 2018 Nov 10; 289():79-93. PubMed ID: 30149048
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.